Figure 2.
Survival at 4 years of 75 patients with relapse or progression of a BL or B-AL during or after appropriate risk-adapted NHL-BFM front-line therapy between 2001 and 2016. According to the initial therapy branch (A), and according to the reinduction regimen (B).

Survival at 4 years of 75 patients with relapse or progression of a BL or B-AL during or after appropriate risk-adapted NHL-BFM front-line therapy between 2001 and 2016. According to the initial therapy branch (A), and according to the reinduction regimen (B).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal